Healthtech Series B Investors & VC Firms
1027 firms in this list, with a median first check of $540K. 256 of them lead rounds. Generated from verified public data and updated continuously.
Third Point Ventures
Menlo ParkSeed–Late Stage
6 people
Foresight Group
LondonSeed–Growth$1.3M – $6.3M
18 people
Yunus Social Business Colombia
BerlinSeed–Growth
33 people
AG Capital Co. Ltd.
TokyoSeed–Growth
1 person
Magna Investment
SeoulSeed–Growth
17 people
QVentures
LondonPre-Seed–Growth$127K – $6.3M
5 people
Save the Children Global Ventures
Series A–Growth$150K – $500K
25 people
Xeraya Capital
Kuala LumpurSeed–Growth
22 people
Kennet Partners
LondonSeries B–Growth$8.6M – $32.4M
18 people
Adjuvant Capital
New YorkSeries A–Series B$10M – $25M
19 people
BeiGene
ChangpingSeries A–Series B
38 people
Solas BioVentures
ChattanoogaPre-Seed–Series B
17 people
LAV
Hong KongSeed–Series C$5M – $15M
3 people
Brightlands Venture Partners
GeleenSeed–Series B$540K – $2.2M
14 people
Verlinvest
BrusselsSeries A–Growth
15 people
Sunstone Capital
FrederiksbergSeed–Series B
11 people
Tanglin Venture Partners
SingaporeSeed–Series B$8M
20 people
9Yards Capital
New YorkSeries A–Growth$100K – $10M
6 people
Augment Ventures
Ann ArborSeed–Series B
16 people
Leonid Capital Partners
WashingtonSeed–Growth
28 people
PeakBridge VC
UtrechtSeed–Series B
15 people
JUXTAPOSE VENTURES
New YorkSeed–Growth
22 people
Innova Capital Sp. z o.o.
WarsawSeries B–Late Stage$27M – $44M
5 people
SucSEED Indovation
HyderabadPre-Seed–Growth
11 people
Related lists
Healthtech Investors & VC Firms (4190)Healthtech Seed Investors & VC Firms (3233)Series B Investors & VC Firms (2946)Healthtech Investors & VC Firms in North America (2665)Healthtech Investors & VC Firms in United States (2436)Healthtech Series A Investors & VC Firms (2309)Series B Investors & VC Firms in North America (1736)Series B Investors & VC Firms in United States (1571)Healthtech Pre-Seed Investors & VC Firms (1468)Healthtech Investors & VC Firms in Europe (1357)
Data sourced from public filings and firms' own websites — see our methodology.




























































































